Baudax Bio, Inc. (BXRXQ)

Market Cap	52.00 -100.0%
Revenue (ttm)	1.27M +217.3%
Net Income	-7.61M
EPS	-1.91
Shares Out	52.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	9,276
Open	0.0001
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	25.33
RSI	39.28
Earnings Date	n/a

About Baudax Bio

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary bloc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 9
• Stock Exchange: OTCMKTS
• Ticker Symbol: BXRXQ

Financial Performance

In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.